Check out poster #ST028 Association for Molecular Pathology today. @PGDx presents their validation study on plasma focus, an #NGS assay designed for solid tumor profiling from cfDNA. This assay reports SNVs/indels for 33 genes, amplifications in 8 genes, gene fusions in 5 genes and MSI. #AMPath22 #AMPlifier

We performed CGP on 3288 samples using @OmniSeqInsight’s NGS assay. We identified 16 NRG1 fusions – with an incidence of 0.4%. RNA sequencing increases the detection rate for NRG1 fusions and offers therapy options for patients. Visit our Labcorp poster #AMPath22 #AMPlifier

Congrats MK Anastasio and Dr. Tomi Akinyemiju!

Healthcare Access Dimensions and Guideline-Concordant #OvarianCancer Treatment: SEER-Medicare Analysis of the ORCHiD Study: jnccn.org/view/journals/… @MKMontesdeOca Rebecca Previs Anjali Gupta Maria Pisu Margaret Liang, MD MS Kevin Ward AndrewBerchuck,MD Tomi Akinyemiju PhD #hsronc #GynCSM

We analyzed ClinicalTrials,gov and found <10% of trials enrolling patients with gyn cancers report racial/ethnicity. We need diversity+transparency in enrollment. bit.ly/3Fdz49y Tomi Akinyemiju PhD MK Anastasio Ben Peipert, MD Duke Ob/Gyn Duke Cancer Labcorp Eric Severson

If you will be at the #ASH22 meeting next week, check out my Labcorp teammate, Eric Severson's presentation. 💜 the #ASHaiku! ASH

#ASHKudos to Labcorp’s Eric Severson who presented this morning. #ASH22 ASH 🧪🔬

Standing room only for Dr. Britta Weigelt’s discussion of circulating tumor DNA! #SGO2023 MSK Department of Pathology & Laboratory Medicine SGO

Thank you Annie Ellis and Dee Sparacio for being a voice and a light. We are grateful for your advocacy, leadership, and reminding us of our purpose. #SGOMtg #PatientsPurposeProgress

The data are in! Cryocompression therapy works during chemo and prevents subjective neuropathy in patients with gyn cancers. Congrats MK Anastasio Laura J Havrilesky and Duke Ob/Gyn team. #SGOMtg #PatientsPurposeProgress

Our fellow Pamela Peters discussing her work on MEM-288 under mentor Rebecca Previs proud of her work to improve the understanding of ovarian cancer immune response Duke Ob/Gyn

Checkpoint inhibition has had limited efficacy in high grade epithelial cancer. So proud of Pamela Peters and her work evaluating MEM-288, a novel oncolytic adenovirus, demonstrating efficacy and generating a systemic immune response. #SGOMtg Duke Ob/Gyn #PatientsPurposeProgress

Mentoring is one of life’s greatest privileges—and it’s not about creating clones but giving the space for each to create themselves and their own authentic paths. Couldn’t be prouder of Pamela Peters and Elizabeth Bloom. ⭐️ 👩‍🔬🔬🧬🧪#WomenInSTEM #sgomtg #PatientsPurposeProgress

Check out Elizabeth Bloom’s work today at #SGOMtg. She reports a molecular analysis of a retrospective cohort of patients with endometrial intraepithelial hyperplasia. 5% were dMMR; 4% were p53abn. Duke Ob/Gyn #Previslab Kyle C. Strickland, M.D., Ph.D. Pamela Peters Janice Wong 🧪🔬👩‍🔬🧬

👏🙌NRG GY018!! We did it - improved progression free survival in MMRd AND MMRp #EndometrialCancer. Standard of care == CHANGED! #SGOMtg #gyncsm #ImmunoOnc Congrats to NRG Oncology

Want to learn more about HER2-low breast cancer? Please tune into this webinar by my amazing colleague and oncologist, Dr. Rebecca Previs as she leads important discussions around HER2-low breast cancer! 🙌🏻

One more week until our live Ask the Expert Q&A with Labcorp's Rebecca Previs! Join us to learn how #personalized #medicine is transforming #breastcancer treatment and explore emerging targeted therapies for HER2-low breast cancer subtypes: us02web.zoom.us/webinar/regist…

Comprehensive Genomic Profiling: A Required Tool for Precision Oncology ASCO The ASCO Post OncoAlert #ASCO23 Gil Morgan, MD ascopubs.org/doi/10.1200/AD…